CASE PRESENTATION
A 36-year-old female visited our clinic because of visual field defects lasting for 1 week. She had suffered from acute lymphocytic leukemia and fungal pneumonia after chemotherapy. On examination, the best-corrected visual acuity was 5/60 in the right eye and 6/5 in the left eye. The anterior segment was silent, except for slightly sluggish light reflex in the right eye. Fundoscopy showed clear vitreous and subretinal abscesses in both eyes ( Figure 1 ). Although the blood culture was negative, systemic antibiotic and antifungal agents were given empirically because of the clinical imaging and history. The abscesses resolved gradually in both eyes ( Figure 2 ). The vision also recovered to 6/7.5 in both eyes. Unfortunately, Choroidal neovascularization is a major cause of visual loss in age-related macular degeneration. It is also a potential vision-threatening complication of pathologic myopia, uveitis, traumatic choroidal rupture and, rarely, endophthalmitis. Here, we report a 36-year-old woman with acute lymphocytic leukemia and fungal pneumonia after chemotherapy who developed endogenous endophthalmitis in both eyes. The infection was controlled by systemic antibiotic and antifungal agents. Unfortunately, choroidal neovascularization developed in the right macula 1 month later. One dose of intravitreal injection of ranibizumab (0.5 mg/0.05 mL) was given, and the macular exudates resolved rapidly. There was no recurrence or complications during the 10-month follow-up. recurrent blurred vision developed in the right eye 1 month later. Ophthalmological examination showed no recurrence of endophthalmitis but a grayishgreen lesion was found in the right macular center. Fluorescein angiography showed an early hyperfluorescent lacy net and late leakage in the macular center. Optical coherence tomography (OCT) revealed the presence of CNV and macular edema (Figure 3 ). Intravitreal injection of ranibizumab (0.5 mg/0.05 mL) was given soon after diagnosis, and the macular exudates decreased rapidly. OCT showed resolution of macular edema and the disappearance of the previously seen CNV membrane. Best-corrected visual acuity recovered to 6/7.5. According to the clinical imaging and OCT findings, the CNV was believed to have regressed although fluorescein angiography was not repeated because of her systemic condition. There was no complication or recurrence during the 10-month follow-up ( Figure 4 ).
INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO ENDOGENOUS ENDOPHTHALMITIS

DISCUSSION
CNV, if located in the macula, usually causes profound central vision loss. It occurs mostly in AMD, and has been reported as a potential visionthreatening complication of pathologic myopia, uveitis and traumatic choroidal rupture [1] . It is also rarely reported as a complication associated with endophthalmitis [2] . In this report, the patient with leukemia had previously undergone chemotherapy, which was complicated by fungal pneumonia.
Although no cultures were taken from an ocular specimen to confirm the diagnosis, endophthalmitis was diagnosed based on the clinical findings and the effects of antibiotic and antifungal treatment. Intravitreal injection of anti-VEGF was recently reported to be a safe and effective treatment for CNV secondary to AMD, pathological myopia and uveitis [3] . Photodynamic therapy has also been reported to be useful in arresting the progression of CNV secondary to Candida endophthalmitis [2] . However, because of the risk for retinal pigment epithelium damage and the immunocompromised status of this patient, intravitreal ranibizumab was used instead [4] . The results of this treatment were encouraging.
In conclusion, intravitreal ranibizumab can effectively and safely treat CNV secondary to endogenous endophthalmitis, even in patients with leukemia. This case also suggests that a single injection of an anti-VEGF treatment during the very early stages can eradicate CNV.
